Management of major depressive disorder following failure of first antidepressant treatment

Primary Psychiatry

Volumn 13, Issue 4, 2006, Pages 73-82

  Shelton, Richard C ^a,b  

^a Department of Psychiatry ^*  (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; ESTROGEN; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; OPIATE DERIVATIVE; PAROXETINE; PINDOLOL; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROXINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

BEHAVIOR THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; EXERCISE; HUMAN; INSOMNIA; MAJOR DEPRESSION; NERVOUSNESS; PHOTOTHERAPY; PRIMARY MEDICAL CARE; REVIEW; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

EID: 33646348699     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998;44(5):348-360.
2. Treatment of Major Depression, Volume 2. Clinical Practice Guideline Number 5. Rockville, MD: Agency for Health Care and Policy Research, US Dept of Health and Human Services, Public Health Service; 1993. AHCPR publication 93-0551. Available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6. chapter.15593. Accessed March 2, 2006.
3. Kerr EA, McGlynn EA, Van Vorst KA, Wickstrom SL. Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement. Jt Comm J Qual Improv. 2000;26(4):203-216.
4. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63(9):826-837.
5. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225.
6. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171-1180.
7. Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med. 1998;28(3):731-735.
8. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108.
9. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504.
10. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262(7):914-919.
11. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22(3):153-162.
12. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 1992;49(10):761-768.
13. Erratum in: Arch Gen Psychiatry. 1993;50(3):241.
14. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608-619.
15. Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry. 2003;64(suppl 2):3-7.
16. Thase ME, Sloan DM, Komstein SG. Remission as the critical outcome of depression treatment. Psychopharmacol Bull. 2002;36(4):12-25.
17. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-855.
18. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57(5):503-509.
19. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28(9):1685-1693.
20. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871-880.
21. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry. 1998;59(suppl 16):13-19.
22. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200.
23. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
24. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409-416.
25. Hollon SD, DeRubeis RI, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):417-422.
26. Ballenger JC. Anxiety and depression: optimizing treatments. Prim Care Companion J Clin Psychiatry. 2000;2(3):71-79.
27. Elavil [package insert]. Wilmington, DE: Zeneca Pharmaceutical 1996.
28. Sinequan [package insert]. New York, NY: Pfizer Inc; 1996.
29. Physicians' Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005.
30. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:1942-1950.
31. Desyrel [package insert]. Corona, CA: Watson Laboratories, Inc.; 2005.
32. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999;60(5):326-335.
33. Stiffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6(1):10-18.
34. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9(3):139-143.
35. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol. 1996;16(3 suppl 2):21S-26S.
36. Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SW. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol. 1998;18(1):19-25.
37. Mehtonen OP, Sogaard J, Roponen P, Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000;61(2):95-100.
38. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(1):57-71.
39. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59(3):116-122.
40. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53(9):785-792.
41. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462-1470.
42. Erratum in: N Engl J Med. 2001;345(3):232.
43. Thompson LW, Coon DW, Gallagher-Thompson D, Sommer BR, Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. Am J Geriatr Psychiatry. 2001;9(3):225-240.
44. Thalen BE, Kjellman BF, Morkrid L, Wibom R, Wetterberg L. Light treatment in seasonal and nonseasonal depression. Acta Psychiatr Scand. 1995;91(5):352-360.
45. George MS, Sackeim HA, Marangell LB, et al. Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr Clin North Am. 2000;23(4):757-783.
46. Hasey G. Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy. Can J Psychiatry. 2001;46(8):720-727.
47. Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ. 2002;167(11):1253-1260.
48. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res. 1990;31(3):287-296.
49. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4-11.
50. Bertschy G, Ragama-Pardos E, Ait-Ameur A, Muscionico M, Favre S, Roth L. Lithium augmentation in venlafaxine non-responders: an open study. Eur Psychiatry. 2003;18(6):314-317.
51. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151(9):1372-1374.
52. Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166(1):80-86.
53. Erratum in: Br J Psychiatry. 1995;166(4):544.
54. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162:634-640.
55. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54(7):269-271.
56. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry. 1996;57(2):72-76.
57. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93.
58. Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry. 1982;139(1):34-38.
59. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990;32(3):241-251.
60. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55(1):11-17.
61. Westlund Tam L, Parry BL. Does estrogen enhance the antidepressant effects of fluoxetine? J Affect Disord. 2003;77(1):87-92.
62. Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58(10):437-439.
63. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999;156(12):2017.
64. Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand. 1980;62(3):193-200.
65. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry. 1989;146(2):278.
66. Mortimer PS, Dawber RP. Hair loss and lithium. Int J Dermatol. 1984;23(9):603-604.
67. Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol. 2004;5(1):3-8.
68. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52(5):217-220.
69. Bouwer C, Stein DI. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997;87(suppl 4):534-537, 540.
70. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998;18(6):465-469.
71. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62(6):448-452.
72. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59(12):664-668.
73. Fischer P, Tauscher J, Kufferle B, Kasper S. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol. 1998;13(2):83-86.
74. Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-271.
75. Joffe RT. The use of thyroid supplements to augment antidepressant medication. J Clin Psychiatry. 1998;59(suppl 5):26-29.
76. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848.
77. Gupta S, Masand P, Tanquary JF. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry. 1991;159:866-867.
78. Appelhof BC, Brouwer JP, van Dyck R, et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab. 2004;89(12):6271-6276.
79. Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003;74(1):5-13.
80. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in chronic major and double depression. J Affect Disord. 2000;60(1):1-11.
81. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157(9):1445-1452.
82. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529-534.
83. Stahl SM. Augmentation of antidepressants by estrogen. Psychopharmacol Bull. 1998;34(3):319-321.
84. American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. ACOG committee opinion. Risk of breast cancer with estrogen-progestin replacement therapy. Int J Gynaecol Obstet. 2002;76(3):333-335.
85. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women viith hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
86. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002;287(5):591-597.
87. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry. 2003;64(suppl 2):14-18.
88. Benazzi F. Venlafaxine-fluoxetine interaction. J Clin Psychopharmacol. 1999;19(1):96-98.
89. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl). 1995;128(4):421-425.
90. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol. 1998;12(5):482-491.
91. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 1999;6(6):322-326.
92. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303-307.
93. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300.
94. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, Shushtari J. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry. 1991;3:209-213.
95. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992;161:562-565.
96. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395-401.
97. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000;61(6):403-408.
98. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58(4):137-145.
99. Marshall RD, Randall D, Johannet CM. Bupropion and sertraline combination treatment for refractory depression. J Psychopharmacol. 1995;9:284-286.
100. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol. 1996;16(1):80-81.
101. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7(2):73-75.
102. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.
103. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 1998;59(3):112-115.
104. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65(1):62-67.
105. Labbate LA, Grimes JB, Hines A, Pollack MH. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997;9(4):241-245.
106. Gerner RH, Kaufman KR, Rosen R. Seizures associated with bupropion and SSRI co-therapy. Biol Psychiatry. 1998;43:99S.
107. Young SI. Panic associated with combining fluoxetine and bupropion. J Clin Psychiatry. 1996;57(4):177-178.
108. Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59(6):306-312.
109. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S; Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21(4):425-431.
110. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ; Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137-146.
111. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61(9):656-663.
112. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23(4):358-364.
113. Erratum in: J Clin Psychopharmacol. 2003;23(6):682.
114. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60(1):45-49.
115. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183-188.
116. Debonnel G, Gobbi G, Turcotte J, de Montigny C, Blier P. The α2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at: 39th Annual Meeting of the American College of Neuropsychopharmacology; February 5-8, 2000; Washington, DC.
117. Gonul AS, Akdeniz F, Donat O, Vahip S. Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):889-891.
118. Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32(4):432-435.
119. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry. 2001;62(2):135-142.
120. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999;60(9):574-579.
121. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12-17.
122. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157:1-45.
123. Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 1999;60(3):142-156.
124. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59(3):233-239.
125. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000;45(5):476-481.
126. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry. 1995;56(1):30-34.
127. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58(1):16-21.
128. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57(3):114-115.
129. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996;57(2):67-71.
130. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64(1):35-39.
131. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HCI: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull. 1989;25(2):272-276.
132. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003;15(1):17-22.
133. Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry. 2001;62(3):185-190.
134. Wan DD, Kundhur D, Solomons K, Yatham LN, Lam RW. Mirtazapine for treatment-resistant depression: a preliminary report. J Psychiatry Neurosci. 2003;28(1):55-59.
135. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001;62(6):413-420.
136. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14(6):419-423.
137. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002;24(7):1194-1200.
138. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1129-1134.
139. de Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol. 1999;19(5):401-406.
140. Reynaert-Dupuis C, Zdanowicz N, Leyman S, Mignon A. Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Prim Care Psychiatry. 2002;8(2):63-68.
141. Thase ME, Lu Y, Joliat M, Detke M. Remission in placebo controlled trials of duloxetine with an SSRI comparator. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
142. Wohlreich MM, Wilson MG, Mallinckrodt CH, et al. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Presented at Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France.
143. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004;61(7):669-680.